Merck＆Co公司的多佐胺．喷吗洛尔（dorzolamide－timolol）复方滴眼液（商品名Cosopt）在美国获得许可用于降低开角型青光眼或眼压高且用β-阻滞剂治疗无效的眼内压升高。本品是第一个将局部用碳酸酥酶抑制剂与局部用p一阻滞剂结合在一起的滴服液。多佐胺-塞吗洛尔复方滴眼液 Dorzolamide from Merck & Co. The dorzolamide-timolol compound eye drops (trade name Cosopt) are licensed in the United States to reduce open-angle glaucoma or elevated intraocular pressure that is associated with high IOP and ineffective with beta-blocker therapy. This product is the first to use topical carbonaraxide inhibitors and topical p-blockers combined with a drop solution. Dorzolamide - seremopolol compound eye drops